ValGenesis seeks to ensure that data created, modified, and stored within its blood banking application are capable of passing internal and regulatory audits, while improving the overall efficiency of validation programs for blood services centers.
With the funds, the company aimed to establish a baseline of pathogens harbored in deer ticks from an endemic area, and expected to create the tools needed to detect these pathogens in human blood, saliva, and urine samples.
More than $85 million in redirected funds identified by the Department of Health and Human Services is being made available to support efforts to protect Americans from Zika infection and associated adverse health outcomes.
According to the companies, Nanosphere’s Verigene technology leads in the high-growth bloodstream infection segment and complements Luminex’s current infectious disease portfolio.
Altona Diagnostics’ test enables qualitative detection of RNA from Zika virus in persons meeting clinical or epidemiological criteria set by the US Centers for Disease Control and Prevention.
Submissions will be considered by patient advocates and the moonshot’s blue ribbon panel of scientific experts as they develop the National Cancer Institute's scientific direction for the initiative.
A new panel will serve as a working group of the presidentially appointed National Cancer Advisory Board, and will provide scientific guidance from thought leaders in the cancer community.
Many tests have been shown both to find cancer early and to lower the chance of dying from the disease.
Two recent studies have demonstrated the benefits of molecular testing in pediatric cases of thyroid lesions.
NanoString Technologies and HalioDx will develop and commercialize advanced gene expression assays for assessing patient response to immunotherapies.
A new study shows that Zika virus infects and crosses the placentas of pregnant mice, and causes severe damage or death in fetal mice
This month's Product News features electronic pipettes, barcoded tubes, and an HIV/AIDS diagnostic device.
Advances in testing techniques are being predicted as moonshot byproducts.
Risk-based decisionmaking and appropriate analytical tools can improve lab quality.
Findings show that data gained through next-generation sequencing of ccfDNA and ctcDNA liquid biopsy templates differ from but complement each other, and should be used in combination.
A study examined patients with early-stage breast cancer who were considered at high risk for disease recurrence.
Genomic insights from the collaboration will be added to a comprehensive database.
Quest Diagnostics has received emergency use authorization for a qualitative, real-time reverse-transcription, polymerase chain reaction test.
Clinical laboratories and in vitro diagnostic manufacturers are working to improve the tools available to track and diagnose the disease.
The molecular immunohematology assay evaluates blood compatibility between donors and patients to help prevent mismatches that can cause life-threatening reactions.